Labelling Compliance: Reducing Recall Risk Through Better Implementation Planning
Labelling and product-information errors remain a significant compliance risk for medicine manufacturers and Marketing Authorisation Holders. Even minor discrepancies such as an incorrect strength, missing warning, outdated leaflet or packaging component with superseded information can affect patient safety, supply continuity and regulatory compliance.
For PharmaGuard Consultancy, reviewing recall and regulatory intelligence is an important part of identifying practical risk areas for clients. Labelling-related issues can arise at multiple points in the lifecycle: regulatory approval, artwork development, manufacturing planning, packaging, batch certification and distribution. The most effective response is not simply to correct an issue when it occurs, but to build an integrated process that prevents it from reaching the market.
Why labelling changes need careful control
Following approval of a change to product information, the revised information should normally be introduced at the next packaging run. Where this is not logistically possible, the change must still be incorporated into newly released packs within the permitted implementation period, unless an exceptional alternative timeframe has been agreed with the MHRA. Safety-related changes should be prioritised for implementation at the earliest opportunity.
The six-month implementation window should therefore be treated as an outer limit not a target date. Delays can accumulate quickly where products are manufactured overseas, packaging materials have long lead times, or stock needs to be shipped, tested, released and distributed through a complex supply chain.
Without clear governance, an apparently manageable regulatory change can become a quality, supply or recall issue.
Common causes of labelling failures
Labelling and packaging deviations are rarely caused by a single error. More often, they reflect a breakdown in communication, planning or oversight across several functions. Common root causes include:
Delayed assessment of the impact of an approved regulatory change
Incomplete handover between Regulatory Affairs, Pharmacovigilance, Quality, Supply Chain and manufacturing partners
Artwork approval processes that do not reflect the current approved product information
Insufficient control of obsolete packaging components
Long production or transport lead times not considered in the implementation plan
Limited visibility of batch status, packaging schedules or market stock
Inadequate escalation when implementation dates are at risk
Confusion over country-specific or presentation-specific product information requirements
Packaging and labelling defects can range from administrative non-compliance to errors with direct potential to affect safe use of a medicine. Examples may include incorrect or missing strength information, leaflet or carton discrepancies, missing expiry or batch details, or a product packed in the wrong presentation.
Treat implementation as a cross-functional process
Strong labelling compliance depends on an end-to-end implementation process rather than a Regulatory Affairs task alone. Each approved change should be assessed promptly to establish:
The exact product-information change and its safety significance
The affected packs, strengths, markets and batch presentations
The regulatory implementation deadline and any specific MHRA expectations
Existing component inventory and whether it can continue to be used
The next packaging run and realistic timelines for artwork, procurement, manufacture and release
The potential impact on product availability
Clear accountable owners and escalation points
A robust change-control process gives every relevant function a shared view of the deadline, dependencies and risks. This enables teams to make informed decisions early, rather than reacting when a deadline is already approaching.
What to do when deadlines are at risk
Despite careful planning, circumstances can arise that make the original implementation timeline difficult to achieve. This may be due to supply disruption, manufacturing capacity constraints, unexpected artwork delays or a shortage of compliant packaging components.
When this happens, the priority is to assess both patient-safety impact and supply impact without delay. The assessment should consider the nature of the change, the risk posed by the existing information, the volume and market share of affected stock, available alternatives and the potential for supply interruption.
Possible routes may include, where appropriate and subject to regulatory agreement:
Seeking MHRA advice or agreement on the proposed approach
Exploring an exceptional batch-specific regulatory solution
Repacking or over-labelling, where feasible and compliant
Prioritising or expediting the next compliant packaging run
Implementing targeted supply controls while corrective action is completed
These options should never become routine workarounds. Each requires careful evaluation, appropriate Quality involvement and a clear understanding of the applicable regulatory requirements. The MHRA guidance specifically advises companies to make contact if there is likely to be difficulty in meeting the six-month period.
Building a more resilient system
The most effective way to reduce recall risk is to make implementation readiness part of normal portfolio governance. PharmaGuard Consultancy recommends that organisations consider the following controls:
Create a single regulatory implementation tracker. Include approval date, implementation deadline, affected presentations, artwork status, packaging schedule, batch-release date and accountable owners.
Use risk-based triage. Prioritise changes that affect patient safety, dosing, contraindications, warnings or other critical information.
Hold regular cross-functional review meetings. Regulatory Affairs, Pharmacovigilance, Quality, Supply Chain, Manufacturing and Commercial teams should review upcoming implementation milestones and risks together.
Build escalation triggers into the process. Do not wait until a deadline has been missed. Define when delays, inventory constraints or artwork issues must be escalated.
Control obsolete components rigorously. Ensure outdated cartons, labels and leaflets are clearly identified, reconciled and prevented from unintended use.
Learn from deviations and recalls. Trend recurring issues to identify systemic weaknesses in governance, supplier oversight, artwork management or communication.
How PharmaGuard Consultancy can help
PharmaGuard Consultancy supports pharmaceutical companies with practical, risk-based approaches to product-information implementation and labelling compliance. This can include process mapping, gap assessments, implementation-tracker design, cross-functional governance, training, deviation support and inspection-readiness activities.
Effective labelling control protects patients, helps maintain continuity of supply and reduces the likelihood of costly corrective action. If your organisation would benefit from a review of its regulatory implementation or labelling governance processes, contact PharmaGuard Consultancy at info@pharmaguard.co.uk or via the website contact form.
This article provides general compliance information and should be applied alongside the current product-specific regulatory requirements and MHRA guidance.